TerminatedPhase 3NCT00768300
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Ganesh Raghu, MDUniversity of Washington, Div. of Pulmonary and Critical Care Medicine Chair
- Intervention
- Ambrisentan(drug)
- Enrollment
- 494 enrolled
- Eligibility
- 40-80 years · All sexes
- Timeline
- 2008 – 2011
Study locations (30)
- University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
- Pulmonary Associates, Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- David Geffen School of Medicine at UCLA(Harbor-UCLA Medical Center), Los Angeles, California, United States
- University of California, Davis, Sacramento, California, United States
- San Diego, California, United States
- San Francisco, California, United States
- Stanford University, Stanford, California, United States
- National Jewish Medical And Research Center, Denver, Colorado, United States
- Newark, Delaware, United States
- Bay Area Chest Physicians, Clearwater, Florida, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- University of Chicago, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00768300 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center